Beijing Shijitan Hospital Transfers PRF Preparation Device Patent for RMB 350,000

Recently, Beijing Shijitan Hospital, Capital Medical University, released a public notice on the transformation of scientific and technological achievements, regarding“A Preparation Device for Platelet-Rich Fibrin and Its Preparation Method”Invention patent, successfully transferred to Wuhan W.E.O.Science&Technology Development Co.,Ltd through the transfer of patent application rights, with a contract amount ofRMB 350,000. The proceeds from this transfer will be distributed in accordance with hospital regulations, with 70% awarded to the individuals and team responsible for the achievement, and 30% allocated to support the hospital’s subsequent technology transfer and management efforts. The inventors of the patent involved in this transfer areProfessor Bai Wenpei and Her R&D Team。

The patents involved in this transfer provideA Fully Enclosed, Integrated Device and Method for Preparing Platelet-Rich Fibrin (PRF), with its core value lying in the thorough revolutionization of traditional preparation processes. Through an ingenious concentric sleeve design (comprising an injection tube assembly, a piston tube, and a centrifuge tube body) combined with a multi-level sealing structure, this technology seamlessly integrates multiple independent steps—blood collection, centrifugation, separation, and injection—into a single sealed system. This approach not only greatly simplifies operations but also fundamentally eliminates the risk of bacterial contamination arising from cumbersome procedures and instrument transfers, thereby achieving standardized, safe, and efficient PRF preparation and providing clinicians with a reliable one-stop solution.

Platelet-Rich Fibrin (PRF) is a platelet concentrate derived from the patient’s own blood, which effectively promotes wound healing and tissue regeneration. By releasing abundant growth factors, it activates and accelerates the proliferation and migration of local reparative cells, thereby demonstrating broad clinical applicability across multiple medical specialties.

Its indications primarily include intrauterine adhesions, chronic non-healing wounds (such as regenerative repair following skin burns and management of diabetic foot gangrene), as well as applications in dentistry for periodontal tissue regeneration, bone augmentation during dental implant placement, gingival mucosal regeneration, and repair of soft and hard tissue defects after tooth extraction.

PRF exerts its reparative effects primarily through three major components. First,Cellular Components, which is rich in activated platelets and also contains small amounts of white blood cells and red blood cells. Upon activation, platelets can release various key growth factors. Secondly,Temporary Extracellular Matrix, which is primarily composed of a fibrin network formed by the polymerization of autologous fibrinogen in the blood, and incorporates adhesive proteins such as vitronectin to jointly construct a stable three-dimensional scaffold.

This reticular structure is clearly visible under scanning electron microscopy, and its uniform equilateral connectivity is particularly conducive to the directed migration and regeneration of cells such as endometrial epithelial cells. Finally,Abundant Bioactive MoleculesPRF contains over 100 cytokines and proteins that act synergistically on wounds to modulate inflammation, promote angiogenesis, and stimulate cell proliferation. This three-dimensional network, with fibrin as its scaffold, essentially serves as a bioactive scaffold that provides an ideal microenvironment for the attachment, migration, and growth of new cells.

However, the current standard operating procedures for the clinical acquisition and preparation of PRF remain cumbersome and carry inherent risks. The conventional method involves first collecting whole blood from the patient’s vein and immediately subjecting it to centrifugation. After centrifugation, the blood separates into layers, with the upper layer being the desiredPRF Gel Layer, the lower layer isRed Blood Cell Clots。

Subsequently, the blood collection tube containing PRF is transported to the operating room. At the bedside, the lead surgeon must personally perform the procedure under open conditions: using sterile forceps to extract the PRF gel from the tube, followed by careful trimming with sterile surgical scissors to remove excess red blood cell clots adhering to the bottom of the gel. Finally, the surgeon typically uses a delivery device improvised from a 1 mL syringe to administer the processed PRF gel to the target site, such as the uterine cavity.

Although these procedures must be performed under sterile conditions, the involvement of multiple open steps and instrument exchanges significantly increases the risk of sample exposure to air and subsequent bacterial contamination. The complexity of the entire process also results in prolonged operation time, high dependence on the operator’s technical skills, and difficulty in ensuring consistency and stability across batches of PRF products in terms of morphology, cell viability, and sterility.

Therefore, there is an urgent clinical demand for a novel integrated preparation technology and device that can consolidate blood collection, separation, purification, and infusion into a single closed system, thereby fundamentally eliminating the risk of contamination and enhancing the standardization of PRF preparation as well as the quality reliability of the final product.

To address the core challenges inherent in the aforementioned clinical preparation process, including cumbersome operations, numerous open-system steps, high risk of microbial contamination, and inconsistent product quality, this invention aims toReconstructing the PRF Preparation Process Through an Innovative Integrated Device Design。

The most core advancement and advantage of the platelet-rich fibrin (PRF) preparation device proposed in this patent lies in that,It redefines the entire workflow of PRF, from blood collection to final product acquisition, through a highly integrated coaxial closed system.This device innovatively arranges the centrifuge tube body, piston tube, and syringe assembly in a coaxial nested configuration from the inside out. This structure is not merely a simple physical combination but is designed to achieve seamless integration of functional flows.

The entire system forms a sealed chamber immediately after initial assembly, with the key lying inMulti-Stage Dynamic Seal Design:The junctions between the plunger and the injection tube, between the bottom of the injection tube and the piston tube, and between the piston tube and the inner wall of the centrifuge tube are all hermetically sealed. This completely isolates the internal chamber from the external environment, fundamentally eliminating the risk of microbial contamination caused by sample exposure to air in traditional open operations, and ensuring that the PRF preparation process remains sterile throughout.

The advanced nature of this device is also reflected in its ingenious"Integrated Functional Integration"above. It eliminates the cumbersome steps in traditional methods that require frequent switching among various instruments such as blood collection tubes, centrifuge tubes, surgical scissors, and syringes. Its working principle is coherent and efficient: first, by pulling the syringe barrel backward, the piston tube connected to it slides upward within the centrifuge tube body, thereby actively generating negative pressure in the “through cavity” at the bottom.

This negative pressure state prepares for the subsequent blood collection steps. When the patient’s vein is connected via the blood collection assembly (comprising a blood collection needle, a blood collection tube, and a connector with a pierceable sealing stopper), blood flows smoothly under negative pressure suction through the “flow channel” inside the push rod into the “through cavity” of the centrifuge tube body, thereby completing the primary collection of whole blood.

After blood collection is complete, the entire centrifuge tube can be placed directly into the centrifuge for spinning. Based on differences in the specific gravity of various cellular components in the blood, the centrifugal force separates the contents into two layers: an upper PRF gel layer rich in platelets, white blood cells, and fibrin, and a lower dense layer of red blood cells. At this point, another innovative component of the device—the “rotary cutting assembly”—begins to play a key role. Located at the bottom of the centrifuge tube, this assembly consists of a rotatable “screw-on cap” and a “rotary cutting structure” that passes through it. The “cutting tool” (typically a fine steel wire) at the end of the rotary cutting structure can extend into the lumen.

By rotating the external “control lever,” the operator can precisely adjust the axial height of the cutting tool within the cavity, thereby accurately aligning it with the interface between the PRF layer and the red blood cell layer. Subsequently, further rotation of the control lever drives the cutting tool to rotate, enabling clean and precise separation and excision of the underlying useless red blood cell layer from the overlying PRF gel, akin to a miniature scalpel.

Once separation is complete, the process of obtaining pure PRF becomes exceptionally simple. The operator need only unlock the screw-on cap and then pull back the plunger of the syringe barrel. At this point, the piston-like rubber stopper at the base of the plunger generates negative pressure within the injection chamber, steadily drawing the PRF gel layer located above the cutting plane, along with a portion of the supernatant, into the “injection chamber” of the syringe barrel. Thus, the syringe barrel itself is directly transformed into a PRF-loaded syringe, ready for immediate direct injection or implantation at the surgical site, achieving the integration of “preparation” and “infusion” tools into a single device.

Furthermore, the device incorporates a user-friendly “braking mechanism” that, through the interaction of a support rod and a locking nut, secures the syringe barrel in a fixed position prior to blood collection. This allows for the presetting and locking of the desired blood sample volume, thereby enhancing operational standardization and controllability.

In summary, the advantages of this patented technology are by no means limited to the improvement of a single function; rather, they are achieved through an integrated system of interlocking mechanical designs and fluid control principles,A fully enclosed, integrated, and seamlessly operated new platform for PRF preparation has been developed.It significantly reduces procedure time, lessens reliance on complex aseptic techniques, minimizes points of human intervention and the risk of contamination, ultimately providing a PRF preparation solution with more consistent quality and greater safety and convenience for clinical use.

The technological advantages embodied by this integrated closed-system device point to a broader innovation trend in the field of tissue repair and regenerative medicine: while pursuing clinical operational convenience and safety, the industry is seeking breakthroughs across multiple technical dimensions. Current technological explorations are not limited to optimizing the extraction processes of autologous biomaterials, but are simultaneously advancing toward more upstream"Active Ingredient Substitution" and "Raw Material Production"...and other directions. These parallel R&D pathways collectively expand the possibilities for wound care, and may form a complementary or competitive landscape in the future.

Smith+Nephew Launches CENTRIO Platelet-Rich Plasma (PRP) System.This is an immediate-care system designed to leverage the patient’s own blood components to manage chronic exuding wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure injuries. Its core mechanism involves a single blood draw to separate platelets and plasma, which are then processed into a customizable bioactive blood gel. This gel maintains a moist wound environment and naturally promotes and accelerates the healing process through bioactive components, including growth factors released by platelets. Designed for use in hospitals and clinics, the system allows for tailored gel application based on the wound’s shape, depth, and stage, and its efficacy is supported by two randomized controlled clinical trials.

Currently, the CENTRIO PRP System is being marketed and sold in the United States through an exclusive distribution agreement, marking that the product has entered the commercialization phase.

Propanc Biopharma, Inc.’s Lead Product PRPThis is not platelet-rich plasma (PRP) in the traditional sense, but rather a proprietary, fixed-dose combination of protrypsin and prochymotrypsin. It is a mixture of two zymogens extracted from animal pancreas, administered intravenously at a 1:6 ratio. The therapy received orphan drug designation from the U.S. FDA in 2017. The mechanism of action of this PRP formulation targets cancer stem cells—cells that are resistant to standard therapies and serve as the root cause of cancer recurrence and metastasis. One of its key mechanisms is the reversal of epithelial-mesenchymal transition (EMT). EMT is a critical biological process through which cancer cells acquire migratory and invasive capabilities, leading to metastasis; the zymogen mixture in this PRP can inhibit this process, thereby reducing the metastatic potential of tumors. Preclinical study data show that this PRP inhibited tumor growth by more than 85% in certain animal models and may enhance the sensitivity of drug-resistant tumor cells to chemotherapy.

Currently, PRP has advanced to the clinical development stage. The company plans to initiate a Phase Ib first-in-human clinical trial in Australia in 2026 for patients with advanced solid tumors. Meanwhile, Propanc Biopharma is also actively advancing the research and development of its fully synthetic recombinant candidate drug, Rec-PRP.

From the perspective of future industry outlook, the market for platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) is expected to continue growing, driven primarily by increasing demand for minimally invasive treatments, advances in related medical research, and their proven efficacy in tissue repair. In the future, innovation in this field is likely to focus further on enhancing product standardization and consistency, exploring combination therapies with other treatments (such as stem cell therapy), and lowering operational barriers while ensuring quality through smarter, integrated devices. In this process, balancing technological advancement, clinical accessibility, and reasonable cost will be key to the successful widespread translation of related products.